S22R (p.Ser22Arg) variant of EGFR (Epidermal growth factor receptor)
S22R (p.Ser22Arg) in EGFR (Epidermal growth factor receptor) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The record also includes variant effect predictions, experimental measurements, and structural context.
S22R (p.Ser22Arg) variant details
- p.Ser22Arg
- Ensembl rs2128853494
- Likely benign
- Missense
- MetaLR 0.27
- MetaSVM -0.83
- SIFT 0.33
- EBI: Likely benign
- UniProt: Likely benign
- Structural context available
- Dabrafenib and Cetuximab HT-29 cells, base editing z-scores (predicted consequen: score -0.0683